Last $13.28 USD
Change Today +0.10 / 0.76%
Volume 18.0M
BSX On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 10/31/14 All times are local (Market data is delayed by at least 15 minutes).

boston scientific corp (BSX) Snapshot

Open
$13.27
Previous Close
$13.18
Day High
$13.38
Day Low
$13.26
52 Week High
01/22/14 - $14.08
52 Week Low
10/16/14 - $11.10
Market Cap
17.6B
Average Volume 10 Days
15.9M
EPS TTM
$0.44
Shares Outstanding
1.3B
EX-Date
--
P/E TM
30.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for BOSTON SCIENTIFIC CORP (BSX)

boston scientific corp (BSX) Related Businessweek News

View More BusinessWeek News

boston scientific corp (BSX) Details

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. It offers interventional cardiology products, including coronary stent systems used in the treatment of coronary artery disease; coronary technology products used to treat patients with atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. The company also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters to treat patients with peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat patients with non-vascular disease. In addition, it offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable pacemaker systems, including implantable cardiac resynchronization therapy pacemaker to treat heart failure; and medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart comprising radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, the company provides endoscopy products to treat diseases of the digestive and pulmonary systems; stone management products to treat patients with urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products; and devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs. Boston Scientific Corporation was founded in 1979 and is headquartered in Marlborough, Massachusetts.

23,000 Employees
Last Reported Date: 02/26/14
Founded in 1979

boston scientific corp (BSX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $900.0K
Executive Vice President of Global Operations...
Total Annual Compensation: $517.7K
Executive Vice President and President of Asi...
Total Annual Compensation: $537.3K
Chief Administrative Officer, Executive Vice ...
Total Annual Compensation: $612.0K
Compensation as of Fiscal Year 2013.

boston scientific corp (BSX) Key Developments

Boston Scientific Corporation Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Announces Intangible Asset Impairment Charges for the Third Quarter of 2014; Provides Earnings Guidance for the Fourth Quarter Ending December 31, 2014; Revises Earnings Guidance for the Full Year Ending December 31, 2014; Provides Impairment Guidance for the Full Year Ending December 31, 2014

Boston Scientific Corporation announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net sales of $1,846 million compared to $1,735 million a year ago. Operating income was $64 million compared to $103 million a year ago. Income before income taxes was $3 million compared to loss before income taxes of $40 million a year ago. Net income was $43 million compared to net loss of $5 million a year ago. Basic and diluted EPS was $0.03. Adjusted pre-tax income was $318 million compared to $263 million a year ago. Adjusted after tax income was $273 million or $0.20 per diluted share compared to $230 million or $0.17 per diluted share a year ago. Capital expenditures were $57 million in the third quarter of year 2014 compared to $56 million in third quarter of 2013. The company generated adjusted free cash flow of $330 million and operating cash flow of $346 million in the quarter. Adjusted free cash flow for the quarter was $330 million compared to $291 million in third quarter of last year. For the nine months, the company reported net sales of $5,493 million compared to $5,305 million a year ago. Operating income was $191 million compared to operating loss of $6 million a year ago. Income before income taxes was $45 million compared to loss before income taxes of $282 million a year ago. Net income was $180 million compared to net loss of $229 million a year ago. Diluted EPS was $0.13 compared to basic and diluted LPS of $0.17 a year ago. Adjusted pre-tax income was $938 million compared to $804 million a year ago. Adjusted after tax income was $826 million or $0.61 per diluted share compared to $701 million or $0.51 per diluted share a year ago. For the quarter, the company reported intangible asset impairment charges of $12 million. For the fourth quarter ending December 31, 2014, the company expects GAAP per share results in the range from $0.09 to $0.11, adjusted results per share in the range from $0.20 to $0.22 and estimated amortization expense per share of $0.07. The company estimates sales for the fourth quarter of 2014 in a range of $1.875 billion to $1.925 billion. For the full year ending December 31, 2014, the company expects GAAP per share results in the range from $0.22 to $0.24 and adjusted results per share in the range from $0.81 to $0.83 against prior expectation for GAAP per share results in the range from $0.28 to $0.32 and adjusted results per share in the range from $0.79 to $0.83. Estimated amortization expense per share is $0.28. The company now estimates revenue to be in a range of $7.370 billion to $7.420 billion compared to prior guidance of $7.325 billion to $7.425 billion, which represents growth in a range of 3% to 4% on a reported basis and approximately 5% on an operational basis. The company continues to expect full year 2014 adjusted free cash flow to be approximately $1.2 billion. For the full year ending December 31, 2014, the company expects intangible asset impairment per share of $0.11.

Boston Scientific Corp Mulls Acquisitions

Boston Scientific Corporation (NYSE:BSX) will continue to provide acquisitions and tuck-in acquisitions that strengthen its unique profile in those businesses.

Boston Scientific Receives FDA and CE Mark Approval for New CoverEdge(TM) Surgical Leads for the Precision Spectra(TM) Spinal Cord Stimulator (SCS) System

Boston Scientific Corporation has received U.S. Food and Drug Administration (FDA) and CE Mark approval for the CoverEdge(TM) 32 and CoverEdge(TM) X 32 Surgical Leads. Designed for use with the Precision Spectra(TM) Spinal Cord Stimulator (SCS) System, the CoverEdge Surgical Leads are powered by the Illumina 3D(TM) Software, a proprietary, anatomy-based computer model for precise pain targeting. Boston Scientific is introducing the CoverEdge Surgical Leads at the Congress of Neurological Surgeons (CNS) this week in Boston. Previous surgical leads have delivered pain therapy with a maximum of 16 independent contacts. By offering 32 contacts -- each powered by a dedicated power source -- CoverEdge Surgical Leads are designed to deliver more focused coverage of the spinal cord for more pain relief. Available in two configurations, the CoverEdge 32 Surgical Lead features 32 tightly spaced contacts in four columns for precise pain targeting. The CoverEdge X 32 Surgical Lead offers the broadest span on the market among multi-column paddles. The combination of the CoverEdge Surgical Leads with the Precision Spectra SCS System and Illumina 3D Software is designed to deliver spinal cord stimulation in new ways.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSX:US $13.28 USD +0.10

BSX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $128.70 USD +1.18
Coloplast A/S kr517.00 DKK +15.50
Olympus Corp ¥3,915 JPY +165.00
St Jude Medical Inc $64.17 USD -0.11
Terumo Corp ¥2,732 JPY +196.00
View Industry Companies
 

Industry Analysis

BSX

Industry Average

Valuation BSX Industry Range
Price/Earnings 61.5x
Price/Sales 2.4x
Price/Book 2.6x
Price/Cash Flow 24.3x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BOSTON SCIENTIFIC CORP, please visit www.bostonscientific.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.